Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945700 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9945703 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL17401247 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL17401249 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL8731954 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL17401248 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL42956 | 0.96 | ALDH1A1 (0.48) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL10882313 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL4323031 | 0.93 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 | |
| Potassium SCHEMBL2529395 | 0.93 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807690-B2 | Hyperglycosylated binding polypeptides | GENZYME CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | GENZYME CORPORATION | 2018-04-12 | — | — | US | disclosed |
| US-9790268-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | GENZYME CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170267774-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-9701753-B2 | Hyperglycosylated binding polypeptides | GENZYME CORPORATION (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170107276-A9 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | GENZYME CORPORATION (US) | 2017-04-20 | — | — | US | disclosed |
| US-9580511-B2 | Site-specific antibody-drug conjugation through glycoengineering | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORPORATION | 2016-05-19 | — | — | US | disclosed |
| US-20160060354-A1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | GENZYME CORPORATION | 2016-03-03 | — | — | US | disclosed |
| US-20150079070-A1 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | GENZYME CORPORATION (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140294867-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140271676-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | GENZYME CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8562966-B2 | End-modified poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294867-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | CD2BP2, SIGLEC7, B3GAT3 | ALDH1A1 2289/4885CA12 299/4885CA1 1583/4885 |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | ALDH1A1 2664/4885CA12 3796/4885CA1 4029/4885 |
| US-20150079070-A1 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | UGGT1, B4GALT1, GALNT1 | ALDH1A1 4045/4885CA12 1339/4885CA1 2823/4885 |
| US-20140271676-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | FCGR3B, FCGRT, FCGR2A | ALDH1A1 4742/4885CA12 973/4885CA1 2259/4885 |
| US-20160060354-A1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | CD2BP2, CD74, ENGASE | ALDH1A1 4038/4885CA12 318/4885CA1 1480/4885 |
| US-20170267774-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | SIGLEC9, SIGLEC7, STT3B | ALDH1A1 2864/4885CA12 243/4885CA1 1462/4885 |
| US-11807690-B2 | Hyperglycosylated binding polypeptides | UGGT1, B4GALT1, GALNT1 | ALDH1A1 4045/4885CA12 1339/4885CA1 2823/4885 |
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | CD2BP2, B3GAT3, SIGLEC7 | ALDH1A1 3128/4885CA12 327/4885CA1 1948/4885 |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | FCGR3B, FCGRT, FCGR2A | ALDH1A1 4742/4885CA12 948/4885CA1 2302/4885 |
| US-20170107276-A9 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | FCGR3B, FCGRT, FCGR2A | ALDH1A1 4742/4885CA12 973/4885CA1 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.